Dehaier Medical Signed an Exclusive Distribution Agreement with GCE Group, Europe's Leading Gas-equipment Company

Dehaier Medical Systems Ltd. (DHRM) ("Dehaier"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II products in Mainland China.

EASE II is an automatically triggered high-flow oxygen device, which can be connected with a portable oxygen tank or medical gas pipeline system to deliver high flows of oxygen to patients with minimal breathing resistance.

BSD Medical Reports Significant Growth of MicroThermX® Microwave Ablation System Sales and Equipment Utilization

BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 391% increase in sales for the MicroThermX^® Microwave Ablation System (MicroThermX^®) product line for September 2012, as compared to September 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use equipment rental program and increasing utilization of MicroThermX^® equipment. This is a dramatic increase in sales for MicroThermX^® products and representative of a continuing trend of accelerating MicroThermX^® revenue. MicroThermX^® product sales also grew significantly during the fourth quarter of fiscal year 2012, as compared to the fourth quarter of fiscal year 2011.

BIOLASE Receives FDA Clearance and CE Mark for Its EPIC 10(TM) Diode Soft Tissue Laser

BIOLASE Expects to Achieve Low-End of Revenue Guidance Range in Q3 2012; Commercial Sales Initiated in Countries That Recognize CE Mark Only in Final Days of Q3

BIOLASE, Inc. ( NASDAQ : BIOL ), the world's leading dental laser manufacturer and distributor, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and Conformité Européene (CE) Mark approval for its EPIC 10™ diode soft tissue laser. BIOLASE initiated commercial sales in the final days of the third quarter of 2012 throughout the European Union and in those Asian and Latin American countries that recognize the CE Mark. The Company received notification of clearance from the FDA on October 1, 2012, and immediately began offering the EPIC 10 for sale in the U.S.

FONAR Reports Record Profits From Operations for Fiscal 2012; Net Income Doubles From Fiscal 2011; Revenues Increase 19% to $39.4 Million

FONAR Corporation ( NASDAQ : FONR ), The Inventor of MR Scanning™, reported today its year-end financial results for the year-ended June 30, 2012. The Company has now had nine straight quarters of profitability. For the 2012 fiscal year as compared to the 2011 fiscal year, the Company made improvements in revenues and profit across both of its operating segments, those being the UPRIGHT® MRI segment that includes product sales, service and repair fees, and HMCA, its STAND-UP® MRI center management subsidiary. All of these utilize the FONAR UPRIGHT® Multi-Position™ MRI which is also known as the STAND-UP® MRI.